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Qaiser Bashir,1 Borje S. Andersson,1 Marcelo Fernandez-Vina,1 Leandro de Padua Silva,1
Sergio Giralt,2 Alexandre Chiattone,1 Wei Wei,3 Manish Sharma,1 Paolo Anderlini,1
Elizabeth J. Shpall,1 Uday Popat,1 Morgani Rodrigues,4
Richard E. Champlin,1 Marcos de Lima1We retrospectively analyzed the outcomes of all acute myelogenous leukemia (AML) patients in first remis-
sion (n 5 44; median age 5 48 years; high-risk cytogenetics 5 59%) who received unrelated donor hema-
topoietic cell transplantation (HCT) with myeloablative conditioning regimen of i.v. busulfan, fludarabine, and
antithymocyte globulin (ATG) between January 2002 andNovember 2009 at our institution. Donor-recipient
pairs were matched by high-resolution HLA-A, -B, -C, -DRB1, and -DQB1 typing (10/10 matches, n 5 41;
9/10 matches, n 5 3). With a median follow-up of 34 months, actuarial 3-year event-free survival (EFS)
and overall survival (OS) is 70% and 78%, respectively. The 3-year EFS and OS in patients with and without
poor risk cytogenetics is similar (63% versus 82%, P5 0.43 and 78% versus 82%, P5 .89, respectively). The
3-year EFS and OS is also similar in patients above age 55 year versus patients age 55 year or younger (80%
versus 67%, P5 .47 and 80% versus 78%, P5.81, respectively). The 100-day and 3-year cumulative incidence
of transplant-related mortality is 5% and 15%, respectively. Six patients have relapsed, and 3 of them are alive
and in remission after salvage therapy, with a median follow-up of 23 months. These results indicate that the
majority of AML patients eligible for this treatment can achieve long-term disease control.
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Approximately 70% of adult patients with acute
myelogenous leukemia (AML) achieve first complete
remission (CR1) with induction chemotherapy, but
the great majority relapse without consolidation ther-
apy [1]. Allogeneic hematopoietic stem cell transplan-
tation (HSCT) is generally recommended for patients
with poor-risk cytogenetics and often considered also
for patients with intermediate-risk AML in CR1 [2].
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6/j.bbmt.2010.11.012has limited its more widespread application [3]. How-
ever, newer conditioning regimens have contributed
to a dramatic reduction in the incidence of serious
transplant-related adverse events and transplant-
related mortality (TRM) in the last 10 years [4]. For
instance, myeloablative doses of intravenous (i.v.) Bu-
sulfan (Bu) incombinationwith thenucleoside analogue
fludarabine (Flu) are associated with low toxicity rates,
and possibly lower GVHD incidence [4-8].
Most patients will not have a human histocompat-
ibility antigen (HLA)-compatible donor in the family,
and therefore an unrelated donor (UD) transplant will
be considered. Outcomes after UDbonemarrow (BM)
or peripheral blood (PB) HSCT have also improved
significantly over the last decade, a result of multiple
developments in the field, first and foremost better
HLA typing and donor-recipient matching.
We hypothesized that the use of this reduced-
toxicity regimen, in combination with improved,
high-resolution HLA 5 typed donor-recipient pairs
would lead to improved outcomes comparable to
matched-related donor allogeneic HSCT in patients
with AML transplanted in CR1 [9,10]. Here, we
present our experience, demonstrating that our data
support the use of this conditioning regimen as
described here.1067
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Patients
Eligible for this analysis were all AML patients in
CR1 receiving UD HSCT, consecutively enrolled in
2 prospective clinical trials evaluating the preparative
regimen of busulfan and fludarabine (described be-
low). Primary end point of both trials was time to pro-
gression and overall survival (OS). One patient who
met the criteria for this analysis was treated off proto-
col because of a low left ventricular ejection fraction.
Patients met general eligibility criteria to undergo
myeloablative allogeneic HSCT (age #65 years and
adequate organ function). Disease-specific criteria
included absence of favorable risk cytogenetics
(t[8;21], inv 16, t[15;17]) [11], or the requirement of
more than1 cycleof induction chemotherapy to achieve
CR1 [12,13]. Fourteen patients have been previously
reported [6,8]. All patients signed informed consent,
and were treated between January 2002 and
November 2009. Both prospective clinical trials and
this analysis were approved by the institutional review
board at M.D. Anderson Cancer Center.
Treatment and GVHD Prophylaxis
Fludarabine (Berlex Laboratories, Wayne, NJ) 40
mg/m2/day (days 26 to 23) was administered over
60 minutes, each dose immediately followed by busul-
fan (Otsuka Pharmaceuticals, Edison, NJ), 130 mg/
m2/day or pharmacokinetically (PK2) targeted at an
AUC of 6000 mMol-min 610% (days 26 to 23), ad-
ministered over 3 hours. All patients received either
rabbit antithymocyte globulin (ATG) (n 5 39) (0.5
mg/kg on day 23, 1.5 mg/kg on day 22, and 2 mg/
kg on day 21) or equine ATG (n 5 5) (20 mg/kg/
day on days 23 to 21). All supportive care measures
were previously described [6].
GVHD prophylaxis consisted of tacrolimus (Fuji-
sawaHealthcare, Deerfield, IL) administered for 6 to 9
months if no GVHD, and minimethotrexate (5 mg/m2
on HSCT days 1, 3, 6, and 11) [14]. Pentostatin
(Supergen, Dublin, CA) was added to 14 patients un-
der an investigational protocol on HSCT days 8, 15,
22, and 30, at 1 mg/m2 (n 5 4), or 1.5 mg/m2 (n 5
10) [15]. PB or BM cells were obtained through the
National Marrow Donor Program (NMDP).
HLATyping
All donor-recipient pairs were matched using
high-resolution allele-level HLA typing for HLA-A,
-B, -C, -DRB1, and -DQB1, as previously described
[16]. Up to 1 mismatch was allowed.
Analysis of Donor Chimerism and Engraftment
Chimerism analysis was performed onwhole blood
and on blood mononuclear cells (T and B cells), bypolymerase chain reaction (PCR), with primer sets
flanking microsatellite repeats as described previously
[17]. Neutrophil engraftment was defined to have oc-
curred on the first of 3 consecutive days that the abso-
lute neutrophil count (ANC) exceeded 0.5  109/L of
blood. Platelet engraftment was defined as having
occurred on the first of 7 consecutive days that the
platelet count exceeded 20  109/L, independent of
platelet transfusions.
Statistical Analysis
Actuarial OS and event-free survival (EFS) curves
were estimated using the Kaplan-Meier method [18].
Comparisons between subgroups were performed us-
ing the log-rank test. Data were updated as of February
2010. Cumulative incidence rates were calculated us-
ing the method of Fine and Gray [19]. All tests were
2-sided and P values of .05 or less were considered
statistically significant. Statistical analysis used SAS
version 9 (SAS Institute, Cary, NC) and S-Plus 7
(Insightful Inc, Seattle, WA).RESULTS
Patients
Forty-four patients were transplanted (Table 1).
Ten (23%) were older than 55 years and 26 (59%)
had poor-risk cytogenetics [11]. Three (7%) patients
had 1 donor-recipient HLA-mismatch (9/10) (HLA-
A 5 1; HLA-B 5 1; HLA-C 5 1), whereas 33 (75%)
patients had 1 or 2 HLA-DPB1 mismatches. Median
follow-up is 34 months (range: 4-90).
Engraftment and Chimerism
All patients achieved neutrophil engraftment
(Table 1). The median time to engraftment was 12
days (range: 10-19). Two patients developed second-
ary graft failure associated with severe infections and
drug toxicity. Median T lymphocyte and myeloid chi-
merism at days 30, 100, and 6 months posttransplant
was 100% of donor cells at each time point (Table 1).
Transplant-Related Mortality
Onehundred-day, and 3-year cumulative incidence
of transplant-related mortality (TRM) was 5% (95%
confidence interval [CI], 0.89-1) (n 5 2) and 15%
(95%CI, 0.75-0.97) (n5 7), respectively. TRM causes
were secondary graft failure (n5 1), infection (n 5 4),
acute GVHD (aGVHD) (n 5 1), and regimen-related
toxicity (n 5 1).
Acute GVHD and Chronic GVHD
Grade II-IV aGVHD rate was 23% (n 5 10),
whereas the cumulative incidence of chronic GVHD
Table 1. Patient, Disease, and Treatment Characteristics
Patient Characteristics Values
Median age, years (range) 48 (13–63)
#55 years, n (%) 34 (77)
>55 years, n (%) 10 (23)
Sex, n (%)
Male 20 (45)
Female 24 (55)
Secondary AML, n (%) 9 (20)
Cytogenetic risk category, n (%)
Good* 1 (2)
Intermediate 17 (39)
Poor 26 (59)
Other molecular abnormalities, number/(number of patients tested)
FLT3 (ITD) 2/37
NPM1 mutation 1/3
RAS (NRAS or KRAS) mutation 3/40
CKIT mutation 0/10
t(9;22) 4/8
Median number of chemotherapy cycles to achieve remission (range) 1 (1-3)
Median number of chemotherapy cycles for AML prior to transplantation (range) 4 (2-7)
Median time from diagnosis to transplantation, months (range) 6 (3.7-14)
Median time from first remission to transplantation, months (range) 4.3 (1-12)
Donor-recipient HLA match
(HLA-A,-B,-C,-DRB1,-DQB1 5 10/10)
Yes 41 (93%)
No 3 (7%)
HLA-DPB1 mismatch, n (%)
0 11 (25)
1 22 (50)
2 11 (25)
Hematopoietic progenitor cell source, n (%)
Bone marrow 30 (68)
Peripheral blood 14 (32)
Median number of infused total nucleated cells 3.2  108/kg (range: 0.26-16.26)
Median number of infused CD34 positive cells 3.7  106/kg (range: 0.45-12.36)
Engraftment rate 100%
Median time to neutrophil engraftment 12 days (range: 10-19) (n 5 44)
Median time to platelet engraftment 14 days (range: 8-33) (n 5 43)
Chimerism—median % of donor cells (range)
Transplant day 30
T-lymphocyte; n 5 39 100 (22-100)
Myeloid; n 5 40 100 (98-100)
Transplant day 100
T-lymphocyte; n 5 35 100 (38-100)
Myeloid; n 5 36 100 (35-100)
Transplant day 180
T-lymphocyte; n 5 23 100 (35-100)
Myeloid; n 5 23 100 (98-100)
AML indicates acute myelogenous leukemia.
*Patient presented with central nervous system disease and required more than 1 cycle of induction chemotherapy to achieve complete remission.
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sive cGVHD. The patients who received pentostatin
for GVHD prophylaxis had a lower rate of aGVHD,
(14% [n 5 2], versus 27% [n 5 8] [P 5 NS]), without
an increase in relapse rate.OS
The 3-year OS for the whole cohort was 78%
(95%CI 0.66-0.92) (Figure 1A). The 3-year OS for pa-
tients .55 years and #55 years was 80% (95% CI,
0.59-1) and 78% (95% CI, 0.64-0.94), respectively (P
5 .81) (Figure 1B). The 3-year OS in patients with
and without poor-risk cytogenetics was 78% (95%
CI, 0.63-0.97) and 82% (95%CI, 0.66-1), respectively(P 5 .89). OS was also not influenced by the stem cell
source (P 5 .29).EFS
Within the overall patient population, the Kaplan-
Meier estimate for the 3-year EFS was 70% (95% CI,
0.58-0.86) (Figure 2A). The 3-year EFS for patients
.55 years and #55 years was 80% (95% CI, 0.59-1)
and 67% (95% CI, 0.53-0.86), respectively (P 5 .47)
(Figure 2B). The 3-year EFS in patients with and with-
out poor-risk cytogenetics was 63% (95% CI, 0.46-
0.88) and 82% (95% CI, 0.66-1), respectively (P 5
.43). Similarly, EFS was not influenced by the stem
cell source (P 5 .61).
Figure 1. (A) OS (n5 44; dotted lines represent confidence interval).
(B) OS by age group (.55 years and #55 years).
Figure 2. (A) Event-free survival (n 5 44; dotted lines represent con-
fidence interval). (B) Event-free survival by age group (.55 years and
#55 years).
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Six patients (14%) have relapsed, at a median of 7
months (range: 3-18). Three of the relapsed patients
have died, whereas 2 received a second UD HSCT,
and 1 was treated with low-dose 50-azacitidine [20].
All 3 are currently alive and in CR (median follow-up
23 months), suggesting that salvage therapy is an effec-
tive option for patients who did not develop long-
lasting side effects from the transplant.DISCUSSION
GVHD is a major determinant of TRM rates [21].
We previously observed that aGVHD rate may be
influenced by variable Bu systemic exposure in the
conditioning regimen when using Bu/Flu versus Bu/
cyclophosmaide (Cy) conditioning [22].Moreover, de-
creasing TRM while preserving antileukemic activity
may have a marked impact on outcomes of patients
with AML undergoing UD HSCT. We and others
have conducted nonrandomized retrospective studies
that showed decreased regimen-related toxicity with
the i.v. Bu/Flu conditioning regimen [4,6-8,23,24]. It
is possible that donor choice was the key factor in
preventing more late complications; however, it is
reasonable to hypothesize that the conditioningregimen also led to less delayed complications, given
the favorable early toxicity profile. Our historical data
support this general trend of safer UD HSCT [25].
Themajority of the randomized studies comparing
chemotherapy versus allogeneic HSCT used a donor
versus no-donor approach, based on the availability
of matched sibling donors, with few UD. Most-used
conditioning regimens were Cy combined with either
oral Bu or total-body irradiation (TBI). A recent meta-
analysis of 24 such prospective trials indicated superior
disease-free survival (DFS) and OS for CR1 AML pa-
tients with intermediate- or poor-risk cytogenetics un-
dergoing allogeneic HSCT. These conclusions,
however, were not uniform for all studies, because of
the trade-off between less relapses with higher TRM
(15%-35%) with allogeneic HSCT [26]. Accordingly,
5-year OS for patients with intermediate- and poor-
risk cytogenetics undergoing UD HSCT in CR1 in
a registry study was 29% and 30%, respectively, also
reflecting high failure rates because of TRM [27]. It
is unlikely that patient selection alone explains our re-
sults, but we have to acknowledge that selection was
certainly influenced by the time necessary for donor
procurement. Our patients were granted several
months of remission duration at the time of HSCT.
On the other hand, our cohort met generally accepted
eligibility criteria forUDHSCTusing amyeloablative
Biol Blood Marrow Transplant 17:1067-1071, 2011 1071Unrelated Donor Transplantation for AML in CR1regimen, and included patients up to the age 63 years,
with poor prognosis cytogenetics in 59% of the cases.
In summary, reducing TRM is the fundamental
step to prove the superiority of allogeneic HSCT
over chemotherapy to consolidate CR1 AML. Our re-
sults would suggest that AML patients in CR1 can be
safely treated with UD HSCT, and that the majority
of those eligible for this therapy are expected to
achieve long-term control of their disease.ACKNOWLEDGMENTS
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